Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-20

Study Completion Date

2025-01-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to estimate the frequency of postoperative lasting muscle weakness in patients receiving Sugammadex after undergoing liver transplant surgery by using electromyographic device (EMG), such as TetraGraph.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Train of Four, Tetanus 50 and 100 Hz Recovery After Rocuronium Block Reversed by Sugammadex

NCT05003024

Postoperative Residual Curarization

COMPLETED NA

The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery

NCT04944303

Surgery

COMPLETED NA

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

NCT03519854

Neuromuscular Blockade

COMPLETED PHASE2

Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)

NCT01213264

Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery

COMPLETED

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

NCT04131218

Pharmacokinetics Pharmacodynamics

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TetraGraph monitoring on dominant hand

Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care

TetraGraph on dominant hand

Intervention Type OTHER

Using standard of care TetraGraph device on dominant hand

TetraGraph monitoring on non-dominant hand

Patients receiving sugammadex after undergoing liver transplantation with quantitative monitoring as standard of care

TetraGraph on non-dominant hand

Intervention Type OTHER

Using standard of care TetraGraph device on non-dominant hand

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TetraGraph on dominant hand

Using standard of care TetraGraph device on dominant hand

Intervention Type OTHER

TetraGraph on non-dominant hand

Using standard of care TetraGraph device on non-dominant hand

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients willing to participate and provide an informed consent.
* Patients undergoing primary liver transplantation.

Exclusion Criteria

* Patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
* Patients with systemic neuromuscular diseases such as myasthenia gravis.
* Patients with a known history of cerebrovascular accident (CVA).
* Patients undergoing repeat liver transplantation or concomitant pancreas/kidney transplantation at the time of liver transplantation.
* Patients admitted to the intensive care unit prior to liver transplantation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No